The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial
BACKGROUND: In the past, the role of long-acting beta2-agonists in chronic obstructive pulmonary disease (COPD) relative to other agents has been unclear.
Saved in:
Main Authors: | Kenneth R Chapman, Peter Arvidsson, AG Chuchalin, DP Dhillon, Peter Faurschou, Roger S Goldstein, AF Kuipers |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2002-01-01
|
Series: | Canadian Respiratory Journal |
Online Access: | http://dx.doi.org/10.1155/2002/493296 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
by: Hilla Mills, et al.
Published: (2022-01-01) -
Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID
by: John H Hegarty, et al.
Published: (1997-01-01) -
Retracted: Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
by: Emergency Medicine International
Published: (2024-01-01) -
Salmeterol and Airway Response to Allergen
by: Donald W Cockcroft, et al.
Published: (1997-01-01) -
Salmeterol and Fluticasone Propionate (50/250 μg) Administered via Combination Diskus Inhaler: As Effective as When Given via Separate Diskus Inhalers
by: Kenneth R Chapman, et al.
Published: (1999-01-01)